Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

BackgroundMedullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or m...

Full description

Bibliographic Details
Main Authors: Jingzhu Zhao, Yihebali Chi, Chuanxiang Hu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Dapeng Li, Pingzhang Tang, Ming Gao, Xiangqian Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
medullary thyroid carcinoma
anlotinib
subgroup analysis
older age
bone metastases
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.852032/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.852032/full

Similar Items